Department of Obstetrics and Gynecology, Yonsei University College of Medicine, Seoul, Korea.
Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
J Gynecol Oncol. 2023 Mar;34(2):e51. doi: 10.3802/jgo.2023.34.e51.
In the 2022 series, we summarized the major clinical research advances in gynecologic oncology based on communications at the conference of Asian Society of Gynecologic Oncology Review Course. The review consisted of 1) Ovarian cancer: long-term follow-up data, new poly (ADP-ribose) polymerase (PARP) inhibitors, overall survival (OS) issues with PARP inhibitor monotherapy, hyperthermic intraperitoneal chemotherapy, immunotherapy, and antibody-drug conjugate; 2) Cervical cancer: surgery in early stage disease, therapy for locally advanced stage and advanced, metastatic, or recurrent setting; and 3) Corpus cancer: follow-up regimen, immune checkpoint inhibitor, WEE1 inhibitor, selective inhibitor of nuclear export. A special note was made on the withdrawal of PARP inhibitor from the market for heavily pretreated ovarian cancer patients based on the final OS results of ARIEL-4 and SOLO-3 due to concerns of increased risk of death.
在 2022 年系列中，我们根据亚洲妇科肿瘤学会复习课程会议上的交流，总结了妇科肿瘤学的主要临床研究进展。综述内容包括：1）卵巢癌：长期随访数据、新型多聚（ADP-核糖）聚合酶（PARP）抑制剂、PARP 抑制剂单药治疗的总生存（OS）问题、腹腔热灌注化疗、免疫治疗和抗体药物偶联物；2）宫颈癌：早期疾病的手术治疗、局部晚期和晚期、转移性或复发性疾病的治疗；3）子宫内膜癌：随访方案、免疫检查点抑制剂、WEE1 抑制剂、核输出选择性抑制剂。特别提到了由于 ARIEL-4 和 SOLO-3 的最终 OS 结果显示死亡风险增加，基于大量预处理的卵巢癌患者的 PARP 抑制剂从市场撤出的问题。
